Rocket Pharmaceuticals
RCKT
67 hedge funds and large institutions have $20.7M invested in Rocket Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 18 reducing their positions, and 21 closing their positions.
861% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $106K
17% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.94% less ownership
Funds ownership: 16.53% → 9.59% (-6.9%)
18% less funds holding
Funds holding: 82 → 67 (-15)
43% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 21
81% less capital invested
Capital invested by funds: $109M → $20.7M (-$87.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.66M |
| 2 |
SCM
Sio Capital Management
New York
|
+$1.22M |
| 3 |
SAM
Senzar Asset Management
New York
|
+$739K |
| 4 |
FO
FT Options
Chicago,
Illinois
|
+$499K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$488K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$12.1M |
| 2 |
O
OrbiMed
New York
|
-$11.3M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.15M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$8.05M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.77M |
RCKT Hedge Fund Activity: Q1 2017 in Review
67 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2017, worth a combined $20.7M — down 81% from $109M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of RCKT and 12 opened new positions — a net loss of 9 holders — while 18 trimmed existing stakes and 21 added.
The largest buyer was BlackRock, adding an estimated $1.66M. The largest seller was Jennison Associates, exiting entirely with an estimated $12.1M sold.
- 67 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2017, down from 82 in Q4 2016.
- Funds reported $20.7M of Rocket Pharmaceuticals stock for Q1 2017, down 81% quarter-over-quarter.
- 12 funds opened new Rocket Pharmaceuticals positions in Q1 2017 and 21 closed out, a net change of -9 holders.
- The largest Rocket Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $1.66M added.
- The largest Rocket Pharmaceuticals seller in Q1 2017 was Jennison Associates, an estimated $12.1M sold.
Based on aggregated 13F filings for Q1 2017.